Why You Must Never Sell Samsung Electronics and SK hynix / Hyundai Motor: I Haven't Sold Either; 'This Thing' Will Become Tesla's Equal | Director Lee Young-hoon

삼성전자와 SK하이닉스 절대 팔면 안 되는 이유 / 현대차, 저도 아직 안 팔았어요 "테슬라와 동급이 될 이 것" | 이영훈 이사

Watch on YouTube ↗ | January 25, 2026 at 08:30 | 17:08 | 815 Money Talk (815머니톡)

Speakers

Lee Young-hoon — Director

Hwang Yoo-hyun — Private Banker Team Lead, NH Investment & Securities

Summary

Lee Young-hoon reviews Hyundai Motor's correction and argues it remains a core AI humanoid and autonomous-driving winner. He prefers large memory IDMs Samsung Electronics and SK hynix over semiconductor equipment/materials, and he is positive on KOSDAQ biotech including Samsung Biologics. He also flags steel, low-PBR holding companies, and a maintained shipbuilding/defense/nuclear portfolio as areas to watch.

Lee sees AI expansion into humanoid robots and autonomous driving as the next device cycle.
He argues Hyundai Motor is among only two global leaders prepared for that device cycle and remains attractive despite correction.
He prefers large memory IDMs Samsung Electronics and SK hynix over Korean semiconductor equipment/materials.
He expects a legacy memory re-rating and says selling Samsung Electronics or SK hynix is risky.
He is positive on Korean biotech/KOSDAQ platform bio and sees Samsung Biologics' earnings event as an opportunity.
He recommends watching large-cap Korean steel and low-PBR holding companies on policy and production-cut themes.
He advises maintaining a shipbuilding, defense, and nuclear portfolio.
He warns against FOMO and says investors should reassess if supply/demand conditions change.

Ideas

Lee Young-hoon Director 2:01

Humanoid, autonomous driving are next AI devices.

The core global agenda is AI. Data-center investment is only the early phase; for AI to spread into industry, it needs mass-market devices. The clearest candidates are humanoid robots and autonomous driving, both of which also help offset population decline. These could become the PC/smartphone-like devices that expand the AI cycle.

Lee Young-hoon Director 2:44

Hyundai is a top AI device leader.

Hyundai Motor Group is one of only two companies, along with Tesla, well prepared to build, mass-produce, and sell the key AI devices—humanoid robots and autonomous vehicles. At CES, Hyundai's humanoid technology did not lag Tesla; Atlas targets industrial use while Optimus targets home use, but the markets will overlap. Valuation is not stretched: PBR below 1.1 and P/E around 11-12x versus Tesla's much higher multiples, with a concrete humanoid revenue schedule and potential valuation benchmarks; the speaker has not sold and sees 800k-900k won or higher after consolidation.

Lee Young-hoon Director 7:07

Avoid Korean semiconductor equipment/materials.

The speaker is not interested in Korean semiconductor materials/equipment. In a big-cycle industry, the original manufacturers outperform component suppliers, as seen in shipbuilding. Materials/equipment names are polarized—some make new highs while others can reverse—so the risk/reward is inferior to simply owning the large IDMs.

Lee Young-hoon Director 9:11

Large memory IDMs beat equipment names.

In the memory cycle, large IDMs are better risk/reward than component/materials-equipment names. Memory remains in shortage, major makers are reluctant to add aggressive new capacity because of China catch-up risk and uncertainty over when the AI cycle ends, and they prefer gradual or acquired capacity. This supports pricing and a likely re-rating of legacy DRAM/NAND multiples; Samsung cutting NAND output and raising prices reinforces it. The speaker therefore says owning Samsung Electronics and SK hynix is cost-effective, and selling them may be the riskier choice.

Lee Young-hoon Director 11:41

Korean biotech remains a key overweight.

After earnings season, attention should shift to KOSDAQ and especially biotech. Supply/demand has returned after being washed out, and the speaker plans to increase bio weight. He favors 'real bio' platform companies with genuine technology and concretizing global big pharma collaborations, with the biosecurity law and capacity-expansion themes supporting earnings expectations.

Lee Young-hoon Director 12:10

Samsung Biologics earnings shock is opportunity.

Samsung Biologics' capacity-expansion issue appears to have been cleared by its earnings release. Although the speaker viewed the earnings as a shock even as the market raised targets, he thinks the event can become an opportunity, with biosecurity-law and expansion themes supporting future earnings expectations.

Lee Young-hoon Director 13:41

Watch large-cap Korean steel on cuts.

Steel is worth watching. Production-cut news lifted the sector, and some steel names also have lithium exposure and trade below book value. Government legislation aimed at low-PBR companies could target holding companies and steel. If playing steel, the speaker prefers well-known large-cap steel companies over small or distribution-linked names.

Lee Young-hoon Director 14:02

Watch Korean holding companies on low-PBR law.

Low-PBR legislation could make Korean holding companies and steel companies key targets. The speaker does not name individual holding companies but flags them as worth monitoring for policy-driven re-rating potential.

Lee Young-hoon Director 14:41

Maintain shipbuilding, defense, nuclear portfolio.

The speaker has grouped shipbuilding, defense, and nuclear power as his core portfolio since last year and advises maintaining that portfolio rather than trading around it. Shipbuilding remains an example of a large-cycle theme where the main builders outperformed equipment suppliers and recovered after a temporary pause.

Up Next

삼성전자·SK하이닉스 실적 발표… 29일, 반도체주 급등일까, 셀온 급락일까? / 2월 상승이 기대되는 '이 섹터' | 이경민 부장

815 Money Talk (815머니톡) · Jan 25

"폴란드는 시작일 뿐!" 중동·남미 뚫은 K-방산, 다음 5년이 '진짜' 운명 결정한다. '다음 수출 타겟은 어디?' (LIG넥스원) 디펜스타임즈 안승범 대표

815 Money Talk (815머니톡) · Jan 25

Why Super Group Is Betting on Gambling in Africa

Bloomberg Markets · Jan 25

포스코홀딩스 리튬 호재, 2차전지 소재 ‘탈 중국’ 시작됐다 "2026년 폭등 사이클 다시 온다"ㅣ윤석천 평론가

815 Money Talk (815머니톡) · Jan 25

이 타이밍 놓치면 비뇨기는 끝입니다 | 조정호 골드만비뇨의학과의원 원장 [주말인터뷰]

3PRO TV (삼프로TV) · Jan 25

This 815 Money Talk (815머니톡) video, published January 25, 2026, features Lee Young-hoon discussing Humanoid robotics sector, DRIV, 005380.KS, Korean semiconductor equipment/materials sector, 005930.KS, 000660.KS, KOSDAQ biotech sector, 207940.KS, Korean large-cap steel companies, Korean holding companies, Korean shipbuilding sector, Korean defense sector, Korean nuclear power sector. 9 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Lee Young-hoon · Tickers: Humanoid robotics sector, DRIV, 005380.KS, Korean semiconductor equipment/materials sector, 005930.KS, 000660.KS, KOSDAQ biotech sector, 207940.KS, Korean large-cap steel companies, Korean holding companies, Korean shipbuilding sector, Korean defense sector, Korean nuclear power sector